Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome-Reference-Cited by-同舟云学术

Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome

Published:2016-07-05 Issue:S4 Volume:23 Page:508-515
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Ito Shuhei,Okano Shinji,Morita Masaru,Saeki Hiroshi,Tsutsumi Satoshi,Tsukihara Hiroshi,Nakashima Yuichiro,Ando Koji,Imamura Yu,Ohgaki Kippei,Oki Eiji,Kitao Hiroyuki,Mimori Koshi,Maehara Yoshihiko

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1245/s10434-016-5376-z.pdf

Reference36 articles.

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.

2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.

3. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400–12.

4. Saeki H, Morita M, Tsuda Y, et al. Multimodal treatment strategy for clinical T3 thoracic esophageal cancer. Ann Surg Oncol. 2013;20:4267–73.

5. Morita M, Yoshida R, Ikeda K, et al. Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute. Surgery. 2008;143:499–508.

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of cancer cell‐expressed HLA class I molecules and their immunopathological implications;HLA;2024-05

2. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma;Genome Medicine;2024-04-02

3. Tumor beta2-microglobulin and HLA-A expression is increased by immunotherapy and can predict response to CIT in association with other biomarkers;Frontiers in Immunology;2024-02-22

4. Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy;Frontiers in Oncology;2023-06-22

5. SHFM1 deficiency suppresses esophageal squamous cell carcinomas progression via modulating NF‑κB signaling and enhancing nature killer cell‑mediated tumor surveillance;Experimental and Therapeutic Medicine;2023-03-17